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Targeted therapies designed to specifically target molecules involved in 
carcinogenesis have achieved remarkable antitumor efficacy. However 
resistance inevitably develops and many cancer patients are not 
candidates for these targeted therapies. Furthermore the clinical attrition 
rate continues to rise, which remains a barrier in the development of novel 
targeted therapies. Integration of extensive genomics datasets with large 
drug databases allows us to begin to tackle questions about target 
discovery and drug toxicity with the ultimate goal of accelerating 
personalized anticancer drug discovery. The purpose of this dissertation 
was to address these problems through the development of drug 
repurposing, toxicity prediction, and drug synergy prediction models. 
First to target the role of transcription factors as drivers of oncogenic 
activity, we developed a computational drug repositioning approach 
(CRAFTT) that makes predictions about drugs that specifically disrupt 
transcription factor activity. To do this, CRAFTT integrates transcription 
factor binding site information with drug-induced expression profiling. We 
found that CRAFTT was able to recover a significant number of known 
drug-transcription factor interactions and identified a novel interaction that 
we subsequently validated. Our work in drug discovery led us to ask 
questions about what makes a drug safe. We developed a data-driven 
approach (PrOCTOR) that integrates the properties of a compound’s 
targets and its structure to directly predict the likelihood of toxicity in 
clinical trials and was able to accurately classify known safe and toxic 
drugs. Finally to address the problem of drug resistance, we developed a 
machine learning approach to identify synergistic and effective drug 
combinations based on single drug efficacy information and limited drug 
combination testing. When applied to mutant BRAF melanoma, this 
approach exhibited significant predictive power upon evaluation with 
cross-validation and further experimental testing of previously untested 
drug combinations in cell lines independent of the training set.  
Altogether this work demonstrates how the integration of orthogonal 
datasets gives us power to address difficult questions that are critical for 
precision medicine and drug discovery. Approaches such as these have 
the potential to make a direct impact on how patients are treated, as well 
as to help prioritize and guide additional focused studies. 
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CHAPTER ONE 
INTRODUCTION 
 
Over the past few decades, great strides have been made in the treatment of 
cancer through the adoption of precision medicine approaches. One major effort 
of precision medicine is the greater application of targeted therapies, which seek 
to selectively kill tumor cells. However there are many challenges associated with 
the development and application of these therapies, including identification of 
tractable targets(Gashaw et al., 2011), challenges with drug toxicity(Ledford, 
2011), and drug resistance(Fitzgerald et al., 2006; Komarova et al., 2013). 
Furthermore the rising clinical attrition rate due to biological activity and safety 
issues is a major hurdle for the development of new compounds(Ledford, 2011). 
Therefore approaches that rescue compounds that lack efficacy or identify toxic 
compounds before expensive preclinical and clinical studies have the potential to 
be highly impactful. 
Drug repositioning (or repurposing) is the process of finding new uses for existing 
drugs(Li et al., 2012). Drug repositioning is especially advantageous in terms of 
cost and time efficiency when applied to drugs that have passed human-safety 
and toxicity conditions(Hurle et al., 2013; Li et al., 2012). However, historically, 
drug repositioning has typically been done through a target-based discovery 
method based on a priori mechanistic data(Hurle et al., 2013). Computational 
repositioning methods have begun to emerge largely due to an expansion of 
available data resources(Hurle et al., 2013), e.g. Connectivity Map (CMaP)(Lamb 
et al., 2006) and ENCODE(Encode Project Consortium, 2011). Common 
computational drug repositioning methods include transcriptomic methods, which 
identify existing drugs whose transcriptional profile is inversely and unexpectedly 
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correlated to disease expression signatures(Campbell et al., 2012; Dudley et al., 
2011; Hurle et al., 2013) and methods based on drug side-effects, which seek to 
identify drugs that unexpectedly share side-effects with drugs used against a 
given disease and therefore likely share activity against the disease(Hurle et al., 
2013). There are also many efforts underway that aim to better elucidate the 
mechanisms, targets and effects of drugs. This requires the knowledge of 
protein-protein interactions and pathways, as a drug’s effect on one protein will 
often impact other interacting proteins. This information is then used to direct 
drug repositioning approaches. 
The identification of toxic drugs before they reach the clinic is another critical 
unmet need. Drug likeness measures are commonly used in early stages of drug 
development to weed out compounds with features that are likely to be 
associated with safety issues, such as poor bioavailability(Leeson et al., 2007). 
Additionally before drugs enter human trials, toxicology and efficacy are 
evaluated in animal models. Yet the majority of drugs that have good drug-
likeness characteristics and are safe in animal models still fail in human 
trials(Shanks et al., 2009). 
Another challenge that targeted therapies face is the seemingly inevitable 
development of drug resistance. However it has been proposed that combination 
therapies have the potential to prevent and overcome drug resistance(Fitzgerald 
et al., 2006; Komarova et al., 2013). Indeed there have been a number of 
instances in which drug combinations have been successfully approved and 
utilized to prevent resistance, most notably in the treatment of hypertension, 
asthma, and HIV(Foucquier et al., 2015). There is also great interest in utilizing 
combination therapies for the treatment of cancer and they are FDA approved for 
use in various cancer types(Foucquier et al., 2015). However combination 
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therapies are typically identified in highly focused studies based on detailed 
mechanistic knowledge about each drug. As a result, the large drug 
combinatorial space remains largely unexplored. 
The goal of this thesis is to address these diverse challenges that drug 
development pipelines currently face. Three methods are described which 
address drug repositioning, toxicity prediction, and synergy prediction. The first 
method is a drug repositioning approach that can be used to target drivers of 
oncogenic activity. The second method is machine learning method that directly 
predicts whether a compound is likely to have manageable toxicity in clinical 
trials. The third method is a generalizable machine learning method that can 
predict drug synergy based on limited combination testing.  
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CHAPTER TWO 
A COMPUTATIONAL DRUG REPOSITIONING APPROACH FOR TARGETING 
ONCOGENIC TRANSCRIPTION FACTORS* 
 
PREAMBLE 
This chapter consists of a paper that was published in Cell Reports in June 2016. 
The method (CRAFTT) was conceived in partnership with Dr. Olivier Elemento. I 
implemented the method and subsequent computational analyses. The 
experimental follow-up was done by the Rickman lab (D.R., C.C., E.D.) and the 
electronic medical record analysis by the Tatonetti lab (N.T., T.L., M.R.B.). 
INTRODUCTION 
Transcription factors (TFs) are frequently mutated in cancer. These include 
factors that function in a variety of ways, including nuclear hormone receptors, 
resident nuclear proteins, and latent cytoplasmic factors (Darnell, 2002). Classic 
examples of recurrently altered TFs include the tumor suppressor TF gene p53, 
which is mutated in up to 40% of human tumors (Libermann et al., 2006) and yet 
has remained a highly elusive target for reactivation(Mees et al., 2009). 
Examples also include c-Myc, which is also among the most commonly altered 
genes in cancer(Ablain et al., 2011), and ERG and other ETS-family factors, 
which are fused to the androgen-controlled promoters in over 50% of prostate 
cancer patients (Rickman et al., 2012).  
Inhibition of oncogenes and reactivation of tumor-suppressors have become well-
established goals in anticancer drug development(Darnell, 2002). Yet TFs are 
																																																						
*	Gayvert	KM,	Dardenne	E,	Cheung	C,	et	al.	A	Computational	Drug	Repositioning	
Approach	for	Targeting	Oncogenic	Transcription	Factors.	Cell	Rep.	2016;15(11):2348-56.	
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generally considered difficult to drug (Mees et al., 2009). If a strategy could be 
developed for safely and effectively modulating the activity of specific TFs, it 
would have a broad impact on the treatment of tumor types and subtypes driven 
by oncogenic TFs. In theory a similar strategy could be applied to reactivate the 
lost activity of tumor suppressive factors. Potential mechanisms for 
pharmacological activation or inhibition include disruption of direct DNA binding, 
perturbation or prevention of the interaction with cofactors and other interacting 
proteins(Libermann et al., 2006), as well as disruption or activation of upstream 
signaling mechanisms(Mees et al., 2009). Disrupting interactions with co-factors 
and other regulatory proteins is broadly viewed as one of the most promising 
approaches to altering the activity and function of TFs implicated in disease.  
One of the first and best-understood successes in disrupting TFs was the 
identification of the combination of retinoic acid and arsenic trioxide for inhibition 
of the PML/RARA fusion oncogene in acute promyelocytic leukemia (APL). The 
PML/RARA fusion results in the repression of many genes, which in turn blocks 
the differentiation phenotype that is characteristic of APL(Ablain et al., 2011). The 
retinoic acid-arsenic combination induces PML/RARA degradation which 
reactivates the silenced genes(Ablain et al., 2011). A small-molecule, JQ1, was 
recently discovered to inhibit c-Myc and n-Myc, both key regulators of cell 
proliferation, by inhibiting BET bromodomain proteins which function as 
regulatory factors for c-Myc and n-Myc(Delmore et al., 2011; Puissant et al., 
2013). While important, these studies are based on extremely detailed 
knowledge of the mechanisms and structures of the co-factors required for TF 
activity. Such knowledge is not always available and as a result there is no 
systematic way to identify small molecules that can specifically disrupt TF 
activity.  
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To address this unmet need, we developed CRAFTT, a broadly applicable 
Computational drug-Repositioning Approach For Targeting Transcription factors. 
Altogether, our method provides a broadly applicable strategy to identify drugs 
and small molecules that specifically target the activity of individual TFs. Since a 
significant number of tumors are driven by oncogenic TFs or have lost tumor 
suppressive TFs, our approach could potentially have an important impact on the 
development of new therapeutic strategies. For example, our method may be 
applicable to other therapeutically elusive factors with oncogenic activity, such as 
FOXA1 or for reactivating the expression program of tumor suppressive TFs 
such as p53. 
 
RESULTS  
Computational drug repositioning approach rediscovers JQ1 for MYC 
inhibition 
We first set out to quantify the prevalence of somatic mutations in TF genes. We 
found that 45.1% (p<0.001, Permutation test) of cancer samples in COSMIC 
reported a mutation in a TF. Furthermore TFs constitute a significant proportion 
(18.1%) of the genes in the Sanger caner gene census (Figure 2.1). This 
confirmed that the prevalence of genomic alterations in TF genes in cancer is 
indeed substantial and further indicates that TFs should constitute a major class 
of anticancer drug targets.  
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Figure 2.1 - Analysis of COSMIC and TCGA reveals high prevalence of transcription factor 
mutations in cancer, Related to Figure 1. Frequency of alterations in COSMIC for 
transcription factor and kinase genes. Statistical significance was assessed for each 
category for using a permutation test with 1000 random gene sets of the same size. 
Statistical significance for the comparison of transcription factor to kinase alteration 
frequency was assessed using the chi-squared test. (**p < 0.01, ***p < 0.001). 
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To address this need, we reasoned that if drugs could be identified that 
specifically disrupt the expression of the direct target genes of a given TF, then 
these drugs would represent good candidates for perturbing the driving role of 
that particular TF in cancer. We propose CRAFTT, a Computational drug-
Repositioning Approach For Targeting Transcription factor activity. CRAFTT 
consists of two major steps: (1) prediction and (2) prioritization using network 
analysis.  
For the prediction step, we compute a score that represents how the direct 
targets of a TF are modulated by a particular drug. Direct transcriptional target 
genes are identified using ChIP-seq binding data. The drug treatment-induced 
modulation profiles are obtained by analyzing expression profiles from drug 
perturbation experiments, such as those in the Broad Institute’s Connectivity Map 
(CMap)(Lamb et al., 2006), and generating ranked gene lists by sorting the 
genes from most down-regulated to most up-regulated upon treatment. For a 
given TF and drug pair, we implement the Broad Institute’s gene set enrichment 
analysis (GSEA)(Subramanian et al., 2005) approach using the drug-induced 
ranked gene list and the TF’s direct target gene set. Each GSEA analysis yields 
a normalized enrichment score (NES) and corresponding p-value indicating 
whether the TF target gene set is mobilized as a whole by the drug, either 
towards down-regulation (NES>0) or up-regulation (NES<0). p-values are 
corrected for multiple testing using family-wise error rate (FWER) controlling 
procedures. This multiple testing procedure is applied to each drug perturbation 
profile individually, correcting across all TF gene sets that we are testing. We 
consider a drug to be predicted to affect TF activity if the FWER adjusted p-value 
for the pair was less than 10% (FWER<0.1). 
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Next we use network analysis to prioritize the predictions made in the first step of 
CRAFTT. We reasoned that if many of our predictions are indeed true drug-TF 
modulatory interactions, the network path between drug and their predicted 
target TF should be relatively short. This is due to the presumed mechanisms 
underlying the interaction, which would involve signaling molecules immediately 
upstream of TFs in signaling pathways and transcriptional co-factors. More 
broadly, we expected that drug and target TFs would be functionally related and 
therefore be located in vicinity of each other in a global drug-protein network. We 
curated a biological network that contains 22,399 protein-coding genes, 6,679 
drugs and 170 TFs. The protein-protein interactions represent established 
interactions(Aksoy et al., 2013; Das et al., 2012; Khurana et al., 2013), which 
include both physical (protein-protein interactions) and non-physical 
(phosphorylation, metabolic, signaling, regulatory) interactions. The drug-protein 
interactions were curated from several drug target databases(Aksoy et al., 2013; 
Knox et al., 2011).  
For each drug-TF pair, we calculated the network path length (shortest path) 
between the TF and the drug. To account for the biases associated with TFs or 
drugs with large numbers of targets we calculated a normalized path length, 
which we defined to be the probability that the path length would be observed 
given randomized networks that conserved TF and drug degrees(Gobbi et al., 
2014). We then generate a final prediction score, which we term the modulation 
index (MI). The MI is a weighted score that scales the NES score for the drug-TF 
pair (NESd,TF) by the normalized network path length (NPLd,TF). We note that the 
proposed approach does not make any assumptions about the mechanisms by 
which a drug can disrupt the expression program of TFs (Figure 2.2A). Such  
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Figure 2.2 - Methodology overview. 
A. Alterations in transcription factors are frequently observed in tumors, leading to 
aberrant activity. Our method integrates transcriptional binding data and drug-
induced gene expression profiles to make predictions about drugs that may affect 
transcriptional activity. This disruption can occur through a variety of mechanisms, 
including the inhibition or reactivation of direct binding to DNA or disruption via 
cofactors.  
B. Application of our method to JQ1 expression profiles and MYC ChIP-seq. The (left) 
panel illustrates the results for the GSEA involving JQ1 and MYC. The lowest plot in 
the left panel shows the log2 differential expression profile for JQ1, with the locations 
of the MYC target genes marked directly above. Directly above that are the running 
enrichment score and a histogram of the MYC target gene frequency across the 
drug-induced ranked list, which illustrate whether the MYC target gene set is 
enriched in the under- or over-expression regions. In the (middle) panel, the shortest 
path between JQ1 and MYC is shown, with BET Bromodomain proteins lying 
between the two. On the (right), we illustrate that the application of JQ1 results in the 
downregulation of MYC target genes. 
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disruption can occur in a variety of ways, e.g., disruption of interaction with co-
factors and DNA binding disruption.  
As a first proof-of-principle, we applied this approach to JQ1-induced gene 
expression profiles derived from a recent study(Puissant et al., 2013), all CMap 
drug-induced expression profiles(Lamb et al., 2006), and to MYC direct target 
genes, which were derived from ENCODE ChIP-seq data(Encode Project 
Consortium, 2011). We found that JQ1 significantly down-regulated a substantial 
fraction (47%) of the 1,250 MYC direct target genes identified by ChIP-seq 
(FWER<0.001). Furthermore we found that JQ1 had the lowest FWER adjusted 
p-value, highest enrichment score (NES= 5.12) and the shortest possible network 
path length of 2 given the underlying mechanisms of the true interaction. This 
indicated that JQ1 is the best candidate (MIJQ1,MYC= 5120) out of the 1,310 drugs 
that we investigated. Thus, as predicted, our method correctly identified the 
inhibitory effect of JQ1 on MYC-induced transcription (Figure 2.2B).  
Systematic drug-TF analysis predicts that candidate small molecules can 
disrupt TFs 
We next applied our drug repositioning approach to 166 ChIP-seq experiments 
from ENCODE(Encode Project Consortium, 2011) and to the 1,309 drug 
perturbation experiments in CMap(Lamb et al., 2006). This approach identified 
37,638 candidate drug-TF pairs (out of 218,603 possible combinations) (Figure 
2.3A). These candidates included 21,495 predicted activating interactions (a drug 
induces activation of many direct TF targets) and 16,143 inhibiting interactions (a 
drug induces repression of many direct TF targets). In particular, there were 
1,673 selective predictions involving 49 TFs and 1308 drugs that we have greater 
confidence in due to the selectivity of the prediction. 
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Several predicted drug-TF interactions are consistent with the known activity of 
the drugs involved. For example, all four known HSP90 inhibitors that were both 
included in our biological network and in CMap were predicted to repress HSF1 
activity, which was expected given HSP90’s chaperone effect on HSF1(Conde et 
al., 2009). These four HSP90 inhibitors were radicicol (FWER=0.054), 17-AAG 
(FWER=0.031), 17-DMAG (FWER=0.085), and geldanamycin (FWER<0.001). 
Additionally novobiocin, whose antagonism of HSP90 is reported in literature but 
was not annotated in our network, was also recovered by CRAFTT for disruption 
of HSF1 (FWER=0.031). Novobiocin and geldamycin had been previously 
identified to disrupt HSF1 activity through inhibition of HSP90 chaperone activity, 
operating through the inhibition of HSP90 autophosphorylation for novobiocin 
and the binding to the HSP90 site in geldanamycin (Conde et al., 2009). We 
found experimental evidence for numerous other predicted drug-TF interactions 
for both inhibition and reactivation. 
Since experimental validations are not available for the majority of all drug-TF 
pairs, we turned to network analysis to further evaluate the prediction step of our 
approach. Within our curated biological network, there were 35 known drug-TF 
interactions that were also present in both the ENCODE and CMap datasets. The 
majority of these combinations involved a GR agonist (26 combinations) or a 
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Figure 2.3 - Systematic analysis of 166 TFs and 1309 drug perturbation experiments 
identifies approximately 38,000 candidate TF-drug pairs.  
A. Heatmap of the FWER p-values for all TF-drug pairs involving 168 TFs from 
ENCODE and the 1309 drugs from CMap. In the middle panels, we highlight a 
subset of non-predictions with high GSEA FWER scores (top) and predictions with 
low GSEA FWER scores (bottom). On the right, we illustrate that we would expect 
the candidate TF-drug pairs to have shorter network path lengths than non-
predictions. For example, the non-predicted pair ETS1-betazole (p=1, GSEA nominal 
p-value) has a path length of 4 while the predicted pair FOXA2-prochlorperazine 
(p<0.001, GSEA nominal p-value) has a path length of 2. 
B. Normalized network path lengths for the specific predictions (FWER<0.1) and non-
predictions (FWER=1). Statistical significance was evaluated using the Mann-
Whitney Test.  
C. Network visualization of HSF1, all three HSP90 inhibitors covered in CMap and our 
network (monorden, 17AAG, 17DMAG),and four other drugs not predicted to disrupt 
HSF1 disruption (clomifen, yohimbine, oxprenolol, cortisone 
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HDAC inhibitor (7 combinations). Out of the 35 known drug-TF combinations, 
CRAFTT was able to correctly predicted more than expected (n=21, p= 1.708e-
08, Binomial Test). In particular, CRAFTT predicted both the GR agonists 
(p=6.524e-08, Binomial Test) and HDAC inhibitors (p=0.01978, Binomial Test) 
well. Furthermore we observed that the drug perturbation profiles within these 
classes were quite distinct, thus this is not likely due to recovery of the same 
signal. Additionally, about 85% of these combinations were nominally significant 
(p=3.42e-08), which indicates that our approach was able to identify evidence of 
the targeting event. The drug-TF pairs that were not rediscovered generally 
involved drugs or TFs that targeted many genes or were predicted to interact with 
most other drugs or TFs (non-specific). In general, we found that CRAFTT had 
limited predictive ability for drugs with more than 25 targets and TFs with more 
than 2300 target genes. 
To further assess CRAFTT’s predictive ability, we performed a global network 
analysis by computing the network path lengths for all drug-TF pairs that were 
found to be significant (FWER<0.1) in the predictive GSEA step of our approach. 
As described above, we reasoned that true drug-TF interactions should be short 
given the underlying mechanisms of the interactions (Figure 2.3A). Network 
analysis indeed revealed that the network path lengths (normalized shortest 
path) of our predicted specific drug-TF pairs were significantly shorter than the 
path lengths of non-predictions (FWER=1.0) (p=0.00313, Mann-Whitney test) 
(Figure 2.3B). This is illustrated in Figure 2.3C where we show a subnetwork 
centered on HSF1 that includes drugs connected to HSF1 via one or more 
intervening proteins. Predicted HSF1 inhibitors by our transcriptomic approach 
are indeed closer to HSF1 in this subnetwork (red paths) compared to non-
predicted molecules (yellow paths). Altogether, this analysis indicates that our 
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predictions are not random and confirms that many drugs might disrupt TFs by 
targeting regulatory or interacting co-factors. The network analysis provided 
increased confidence in our approach’s predictive capacity. Moving forward, we 
used shorter drug-TF paths to further prioritize drug-TF predictions using our 
combined score (MI).  
 
Identification and validation of small molecules that inhibit the ERG TF 
We hypothesized that CRAFTT could be used to identify molecules that inhibit 
the activity of the pro-invasive, oncogenic TF ERG. This is of an interest due to 
ERG’s overexpression resultant of a tissue specific gene fusion event that occurs 
in as many as 50% of prostate cancer patients. This overexpression results in a 
pro-invasive phenotype in prostate cancer (Elemento et al., 2012; Rickman et al., 
2010; Tomlins et al., 2008). We had previously identified ERG target genes using 
ChIP-seq in RWPE1 benign prostate cells(Rickman et al., 2012). We therefore 
applied our approach to all Connectivity Map drug profiles to identify candidate 
drugs for inhibition of ERG. 
From the prediction step of CRAFTT, we identified eight candidate drugs that 
down-regulate ERG target genes: dexamethasone (FWER=0.086), naproxen 
(FWER=0.048), acemetacin (FWER=0.087), ondansetron (FWER=0.061), 
epitiostanol (FWER=0.069), diloxanide (FWER=0.003), methanthelinium bromide 
(FWER=0.046) and isoflupredone (FWER=0.088). Five of these candidate drugs 
were contained in our biological network: dexamethasone (MI=1015.85), 
naproxen (MI=530.90), acemetacin (MI= 2167.88), ondansetron (MI= 3.35), and 
epitiostanol (MI= 520.99) (Figure 2.4A). An initial network analysis suggested 
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that dexamethasone, naproxen, acemetacin and epitiostanol were the best 
candidates due to their large modulation indices. 
Next we performed an additional analysis to use with our CRAFTT methodology 
to further prioritize our drug candidate list. We used gene expression (RNAseq) 
from RWPE1 prostate cells to filter out genes that have low expression in the 
network, which we defined as RPKM<4. This analysis resulted in dexamethasone 
being identified as the drug with the shortest path length and highest modified 
modulation index (MI=9.26, Figure 2.4B). 
Since dexamethasone has not previously been linked to ERG, we next sought to 
experimentally test our hypothesis that dexamethasone would be able to reverse 
ERG-induced oncogenic phenotypes through disruption of ERG in ERG-
expressing prostate cancer cells. One of the top target genes that was reversed 
by dexamethasone in the CMap profile was the urokinase plasminogen activator 
(PLAU), which is a known ERG target gene that has been previously implicated 
in ERG-mediated cell invasion in multiple cancers and models (Tomlins et al., 
2008). We found experimentally that dexamethasone abrogated expression of 
the ERG target gene PLAU in both DU145 cells expressing ERG and in VCaP 
cells with high endogenous levels of ERG (Figure 2.4C). In comparison, 
dexamethasone was weakly active in the control GFP cells (Figure 2.4C).  
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Figure 2.4 - Identification of dexamethasone as a candidate drug for inhibition of ERG 
activity. 
A. Network visualization illustrating path lengths from ERG to five candidate drugs for 
ERG inhibition (dexamethasone, naproxen, acemetacin, ondansetron, epitiostanol). 
The node sizes correspond to the gene expression levels, with the larger size 
representing a higher expression level. If low expression genes are removed 
(RPKM<4), the path lengths for naproxen and acemetacin are increased while the 
paths from ondansetron and epitiostanol are completely disrupted. The 
corresponding table shows metrics that describe each of these drugs in relation to 
ERG: NES is the Normalized Enrichment Score obtained from GSEA, PL is the 
shortest network path length required to connect ERG to the drug, MI is the 
modulation index and MI * is modulation index respectively after low expression 
genes were removed (RPKM<4). 
B. Application of our method to dexamethasone expression profiles and ERG target 
genes. The (left) panel illustrates the results of the GSEA for ERG and 
dexamethasone. The lowest plot of the left panel shows the log2 differential 
expression profile for dexamethasone, with the ERG target genes marked directly 
above. Above are the running enrichment score and a histogram of the ERG target 
gene frequency, which illustrates whether the gene set is enriched in the under- or 
over-expression regions. The (middle) panel shows a subnetwork including all genes 
that were members of any shortest path between ERG and dexamethasone. The 
(right) panel illustrates our prediction that the application of dexamethasone would 
result in the downregulation of activity of ERG target genes. 
C. ERG target gene PLAU expression by RT-PCR in cell lines expressing ERG (DU145-
ERG, VCaP) and controls (DU145-GFP) after treatment with vehicle or 
dexamethasone. Data are shown as mean ± SEM. Asterisks indicate statistically 
significant differences by paired t test and n = 3 for each condition (∗p < 0.05,∗∗p < 
0.01, ***p < 0.001, ns - not significant). 
D. Cell invasion and migration in cell lines expressing ERG (DU145-ERG) and controls 
(DU145-GFP). The data are shown as mean ± SEM and at n=4 representation 10x 
field of view. Asterisks indicate statistically significant differences by paired t test and 
n = 3 for each condition (∗p < 0.05,∗∗p < 0.01, ***p < 0.001, ns - not significant). 
E. The binding of ERG and a control (IgG) by ChIP-PCR at the promoter of its target 
gene PLAU and at a negative control (ARHGEF) in cell lines expressing ERG 
(DU145-ERG, VCaP). Data are shown as mean ± SEM. Asterisks indicate 
statistically significant differences by paired t test and n = 3 for each condition (∗p < 
0.05,∗∗p < 0.01, ***p < 0.001, ns - not significant). 
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To further test the inhibitory effect of dexamethasone on ERG activity, we treated 
a newly derived ERG over-expressing cell line derived from PTEN-/-/ERGRosa26 
prostate tumors in transgenic mice (Chen et al., 2013). Consistent with the 
commercially available human prostate cancer cells, dexamethasone treatment 
resulted in a dose-dependent decrease in mouse PLAU mRNA expression 
(Figure 2.5A).  
Using cell invasion and migration assays, we then found that dexamethasone 
significantly decreased cell invasion and migration in DU145 prostate cancer 
cells over-expressing ERG, but not in isogenic control cells (Figure 2.4D, Figure 
2.5B). High-resolution microscopic images revealed that dexamethasone helps 
the cells partially regain polarity, which may be a potential mechanism for 
reduced cell invasion (Figure 2.5C). As expected from published literature on the 
mostly invasive oncogenic role of ERG, we found that ERG inhibition via 
dexamethasone treatment had no effect on cell viability in vitro (Figure 2.5D). 
Finally, we found using ChIP-PCR that dexamethasone substantially decreased 
binding of ERG at the PLAU promoter in both DU145-ERG and VCaP cells 
(Figure 2.4E). Altogether, these experimental results support CRAFTT’s 
computationally derived prediction that dexamethasone inhibits ERG activity. 
CRAFTT’s predicted Dexamethasone-ERG interaction is independent of AR 
and GR 
Dexamethasone is a glucocorticoid receptor (GR) agonist, which suggests that 
GR, encoded by NR3C1, may play a role in ERG-mediated gene expression. We 
found that siRNAs targeting NR3C1 mRNA lowered GR levels by 80% in the 
DU145-ERG cells (Figure 2.5E). Although GR seems to play a role in PLAU 
regulation in the absence of ERG, lowering GR levels did not significantly alter  
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Figure 2.5 - Experimental support of dexamethasone for modulation of ERG activity. 
A. PLAU expression by RT-PCR after treatment with dexamethasone in mouse ERG 
over-expressing cell lines derived from prostate cancer tumors in transgenic mice. 
Data are shown as mean ± SEM. Asterisks indicate statistically significant 
differences by paired t test for each dosage compared to 0nM (***p < 0.001). 
B. Cell invasion and in DU145 ERG-expressing cell lines and isogenic controls after 
treatment with vehicle or dexamethasone. 
C. Imaging in ERG/PTEN cells after treatment with vehicle or dexamethasone. 
D. Dose response curves following a 72 hr incubation at the indicated dose of 
dexamethasone for DU145 clones stably over-expressing ERG (orange) or GFP 
(blue) or VCaP (green) cells. 
E. DU145 cells were treated with siRNAs targeting NR3C1 mRNA that lowered GR 
levels by 80% in the DU145-ERG cells. Data are shown as mean ± SEM. Asterisks 
indicate statistically significant differences by two-tailed paired Student’s t test (∗p < 
0.05,∗∗p < 0.01, ***p < 0.001, ns – not significant). 
F. DU145 cells were treated with siRNAs targeting NR3C1 mRNA or controls. PLAU 
expression in DU145 cell lines expressing ERG and controls (GFP) was quantified 
using RT-PCR after treatment with vehicle or dexamethasone. Data are shown as 
mean ± SEM. Asterisks indicate statistically significant differences by paired t test (∗p 
< 0.05,∗∗p < 0.01, ***p < 0.001, ns - not significant). 
G. Quantification of AR, PSA, and TMPRSS2 expression in VCaP after treatment with 
dexamethasone. Data are shown as mean ± SEM. Asterisks indicate statistically 
significant differences by paired t test for each dosage compared to 0 nM (∗p < 
0.05,∗∗p < 0.01, ***p < 0.001, ns - not significant). 
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dexamethasone’s impact on PLAU expression in ERG positive cells (Figure 
2.5F). Additionally, we found that AR target genes were not substantially 
mobilized by dexamethasone and screening of VCaP cells showed that 
dexamethasone had little effect on AR signaling (Figure 2.5G). Altogether, these 
results indicate that dexamethasone-mediated ERG inhibition occurs 
independently of GR and AR signaling. 
We next looked to see what CRAFTT would predict for another 
glucocorticosteroid that is used in the treatment of prostate cancer, prednisone. 
We found that CRAFTT predicted that prednisone would not inhibit ERG activity 
and subsequent experiments involving the active form of prednisone, 
prednisolone, supported this finding. Recent clinical trials for castration refractory 
prostate cancer (CRPC), in the absence of ERG fusion status, have suggested 
that there is an advantage to using dexamethasone over prednisolone, the active 
form of prednisone, due to improved patient PSA response rates (37% on 
dexamethasone compared to 17% on prednisolone)(Venkitaraman et al., 2013).  
Electronic Health Record analyses support CRAFTT’s predictions 
To further investigate the correlation between dexamethasone treatment and 
prostate cancer, we performed a retrospective analysis of electronic health 
records (EHRs) at Columbia University Medical Center (CUMC). Kaplan-Meier 
survival analysis was performed using the time from first-prescription of drug to 
prostate cancer diagnosis (censor point) on an age-adjusted cohort of male 
patients. Significance was assessed using the Cox proportional hazards test. 
Dexamethasone patients had a statistically significant greater likelihood of not 
getting diagnosed with prostate cancer than patients on prednisone (p<0.001), 
patients on simvastatin (p<0.001), and patients on any of the top 100 prescribed 
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drugs (p<0.001) (Figure 2.6A). We next constructed a logistic regression model 
to assess the relationship of the dexamethasone and other control treatments 
and prostate cancer diagnosis independent of known prostate cancer 
confounders. The results of our regression model showed a protective effect for 
dexamethasone administration versus other control treatment groups that was 
independent of other known risk factors. Thus dexamethasone appears to both 
be protective against prostate cancer (perhaps through its inhibitory effect on 
ERG-rearranged tumors as predicted in this study) and more active than 
prednisolone both in its protective effect and in the treatment of CRPC. We note 
that these results are still largely correlative in the absence of ERG molecular 
status for EMR patients, which we could not obtain for this study. 
CRAFTT predicts candidate drugs for reactivating TF activity 
CRAFTT also made predictions about drugs for transcriptional reactivation. We 
found that there was an enrichment of histone deacetylase inhibitors (p<0.0001, 
Permutation test) amongst our reactivation predictions, indicating that CRAFTT is 
successful in identifying true drug-TF interactions. Thus we hypothesized that we 
could identify a drug that reactivates the tumor suppressor TF p53. The 
application of CRAFTT to p53 ChIP-seq (Kittler et al., 2013) and subsequent 
network analysis identified promethazine (FWER<0.001) as a therapeutic option 
for reactivation of p53 activity. Analysis of DTP-NCI60 drug sensitivity data 
(Reinhold et al., 2012) further supported this prediction, as we found that the 
mutant p53 cell lines were significantly more sensitive to promethazine than the 
wild-type p53 cell lines (p= 0.0376, Mann-Whitney test, Figure 2.6B). We next 
looked to see whether any predicted drugs for p53 activity reactivation targeted 
genes had been previously identified as necessary for growth in TP53 deficient 
cells (Xie et al., 2012). We found that seven of the drugs predicted by CRAFTT to 
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reactivate p53 activity target genes from that list: pentetrazol, naftopidil, oxedrine, 
capsaicin, ifenprodil, flumetasone, and dexpropranolol. Altogether this suggests 
that that our approach can be used to identify candidates for reactivation of TFs 
frequently lost in cancer. 
 
 
 
Figure 2.6 – Extended Analyses of CRAFTT Predictions. 
A. Kaplan-Meier survival analysis for time from first-prescription of drug to prostate 
cancer diagnosis (censor point) using an age-adjusted cohort of male patients was 
performed for patients treated with dexamethasone, prednisone, simvastatin and top-
100 prescribed drugs. Statistical significance was assessed using cox proportional 
hazards test for the comparison of dexamethasone to each other drug. 
B. The drug concentration required to inhibit 50% growth (GI50) in mutant p53 and wild-
type p53 cell lines in the NCI DTP. Statistical significance was assessed using the 
Mann-Whitney test. 
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DISCUSSION  
Traditionally, TFs have been considered difficult to drug and attempts at 
identifying drugs that affect TFs unfruitful. While recent breakthroughs have 
begun to experimentally identify molecules that indirectly modulate transcriptional 
activity, we propose a method (called CRAFTT) to do so computationally and 
systematically. Since cancer subtypes are frequently associated with aberrant TF 
activity often due to somatic mutations, our approach has the potential to broadly 
impact the development of new therapeutic strategies in these subtypes. 
We first looked to see if CRAFTT could rediscover known cases of drugs that 
affect TF activity. We found that when we applied our method to transcriptional 
binding site data and drug profiles from known cases, we could indeed 
rediscover these connections. We then used CRAFTT to identify dexamethasone 
as a candidate for inhibition of ERG activity and follow-up experiments supported 
this prediction. We also found that dexamethasone had a similar effect in recently 
isolated mouse cell lines as it did in the human cell lines. This suggests that 
mouse models could be used to further follow-up on the therapeutic use of 
dexamethasone in treatment of the ERG-overexpression cancer subtypes. 
While CRAFTT was successful in the identification of drugs for affecting 
transcriptional activity, there are areas that could further improve its predictive 
capacities. While the shortest path analysis provides support for our predictions 
and is only used in prediction prioritization, we cannot rule out that individual 
predictions may be affected by bad edges, especially in our protein-protein 
interaction network. However a network sensitivity analysis does suggest that our 
network is robust to missing network edges. This is likely due to the high 
interconnectivity of the netwo+rk, which has an average path length of 3.6. This 
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high interconnectivity also explains the bimodality in the normalized path lengths, 
with the first and second peaks corresponding to shorter and longer observed 
path lengths than average for a drug-TF pair with the same network degree 
respectively. 
Additionally, the ChIP-seq that we used to derive binding site data was obtained 
from wild-type TFs. However we note that our approach was able to capture true 
drug-TF interactions, at least in part due to these variants often causing 
constitutive expression and binding of the TF instead of dramatic disruption and 
changes to binding sites. However as more mutant TF binding data becomes 
available, we will be able to adapt and apply our approach in a more targeted 
and physiologically relevant manner. ChIP-seq peak calling procedures are also 
known to be error-prone. While we have taken steps to control for binding 
hotspots, our method will also benefit as improved peak calling methods become 
available.  
Finally, the Connectivity Map data that we analyzed was in a collapsed format, 
which limits the robustness of the predictions. The Broad Institute has recently 
released an updated version of the Connectivity Map, which includes a 1000-fold 
scale up and will better allow us to utilize the variability in replicates. We also 
intend to apply CRAFTT for the identification of candidate drugs for modulating 
the activity of other TFs that are historically elusive but desirable for targeting, 
such as FOXA1 and XBP1. 
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CHAPTER THREE 
A DATA DRIVEN APPROACH TO PREDICTING DRUG TOXICITY* 
 
PREAMBLE 
This chapter consists of a paper that was published in Cell Chemical Biology in 
October 2016. The method (PrOCTOR) was conceived in partnership with Dr. 
Olivier Elemento. I implemented the method and subsequent analyses. Neel 
Madhukar contributed to model interpretation and follow-up analyses. 
INTRODUCTION 
Failures in all phases of clinical trials have skyrocketed over the past three 
decades, with a substantial portion occurring for safety reasons (Hay et al., 2014; 
Ledford, 2011). This is occurring despite improvements in all stages of the drug 
development pipeline (Scannell et al., 2012). One of the key areas of 
improvement has been the screening for drugs likely to fail clinical trials.  
Drug-likeness measures have been widely accepted as a useful guide for filtering 
out toxic molecules in the early stages of drug discovery. Lipinski first proposed 
this concept over a decade ago with his Rule of 5 (Ro5), a set of four 
physicochemical features associated with orally active drugs that were derived 
from analyzing clinical drugs that reached Phase II trials or beyond(Lipinski et al., 
1997). This concept enhanced the drug discovery process by providing a set of 
practical filters that became widely adopted in drug development pipelines. 
However Lipinski noted that the Ro5 is a very conservative predictor and passing 
the rule does not guarantee drug-likeness (Lipinski, 2004). Modified rule sets 
																																																						
*	Gayvert	KM,	Madhukar	NS,	Elemento	O.	A	Data-Driven	Approach	to	Predicting	
Successes	and	Failures	of	Clinical	Trials.	Cell	Chem	Biol.	2016;23(10):1294-1301.	
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have since been proposed, such as Veber’s Rule(Veber et al., 2002) and 
Ghose’s Rule(Ghose et al., 1999), to include more properties associated with 
bioavailability, such as Polar Surface Area, and to improve upon the concept 
proposed by Lipinski. More recently, the Quantitative Estimate for Drug-likeness 
(QED) was proposed as an alternative to rule-based methods (Bickerton et al., 
2012). 
The adoption of drug-likeness concepts early in the drug discovery process has 
been shown to reduce attrition rates (Leeson et al., 2007). However despite 
these advances in identifying potentially toxic drugs, clinical trial attrition rates 
have continued to rise (Hay et al., 2014). While oral bioavailability is highly 
relevant to drug toxicity, there are other factors that also contribute to clinical trial 
toxicity events. To address this problem, we propose a new approach for 
predicting odds of clinical trial outcomes (PrOCTOR). 
 
RESULTS 
Analysis of clinical trials data reveals limitations of structural-based 
approaches 
Drug-likeness approaches have been important and informative in guiding the 
drug development process. However they cannot distinguish drugs with 
unmanageable toxicity profiles from safe ones (Bickerton et al., 2012; Leeson et 
al., 2007). We verified this quantitatively by comparing drugs that have failed 
clinical trials with FDA approved drugs. To this end, we downloaded data from 
The Database for Aggregate Analysis of ClinicalTrials.gov (AACT)  41 39 38 38 38 34 34 
34 34 34 34 34 at ClinicalTrials.gov and extracted the names of the drugs associated 
with 108 clinical trials of any phase that were annotated as having failed for 
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toxicity reasons. The comparative list was developed from the 1013 FDA 
approved drugs that were annotated as FDA approved in the DrugBank 
database(Law et al., 2014).  
For the drugs in these lists, we tested existing methods for their ability to 
distinguish approved drugs from those that failed for toxicity in trials (FTT drugs). 
Most FDA approved drugs pass Lipinski’s Rule of Five(Lipinski et al., 1997) 
(80.6%) and Ghose’s(Ghose et al., 1999) (64.9%) rules, but so do most of the 
FTT drugs (73% Lipinski, 54% Ghose). In contrast, Veber’s rule(Veber et al., 
2002) appears to be a far too conservative measure, with 75.2% of approved and 
92% of FTT drugs being predicted to fail. Finally the QED approach, which 
calculates a continuous score(Bickerton et al., 2012), is also unable to 
significantly distinguish the two classes (p=0.1069, D=0.10703, Kolmogorov-
Smirnov Test). This analysis further highlights the unmet need to develop 
strategies for predicting the likelihood of toxicity in clinical trials. 
Computational approach accurately predicts likelihood of clinical trial 
failure 
Because all of the drug-likeness methods consider only the chemical properties 
of a molecule, we reasoned that a new approach that includes overlooked 
features related to the results of a drugs performance could prove to be highly 
impactful, similar to the effect that adopting sabermetrics had on the baseball 
scouting process as described in Michael Lewis’s Moneyball(Lewis, 2003). A 
specific example is the consideration of target-related properties, such as tissue 
selectivity (an ideal target would be found only in diseased tissue and sparsely 
anywhere else). We suggest that such considerations could be useful in 
determining potential toxic effects.  
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The inferences gained from the analysis of the various methods and the 
consideration of additional characteristics in the prediction of tolerable toxicity in 
clinical trials led to the development of our new approach for predicting odds of 
clinical trial outcomes using random-forest (PrOCTOR). PrOCTOR integrates 
established informative chemical features of the drugs with target-based features 
to produce a classifier that is able to distinguish FDA approved drugs from FTT 
drugs. Random forest(Breiman, 2001b), a decision tree based machine learning 
model, is used to address the classification problem of clinical trial drug toxicity 
(Figure 3.1). The random forest model builds a set of 50 decision trees with a 
subset of features (see below) within each tree and assigns the predicted 
outcome to be the consensus of the trees. 
The set of 48 features describing each drug contains 10 molecular properties, 34 
target-based properties and 4 drug-likeness rule features. Given their established 
validity, we chose to include the molecular properties considered by the Lipinski, 
Veber and Ghose rules. We found that, individually, some of these properties 
had slight but significant power to discriminate between FDA approved drugs and 
FTT drugs when applied to our lists of drugs in the two categories (Figure 3.2A). 
Additional features represent the compatibility of the compounds with the drug-
likeness approaches. Each drug’s known targets were annotated from the 
DrugBank dataset (Law et al., 2014) and used to derive an additional set of 
target-based properties. We considered the median expression of the gene 
targets in 30 different tissues, such as the liver and the brain, calculated from the 
Genotype-Tissue Expression (GTEx) project(Consortium, 2015). Other target- 
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Figure 3.1. Method Schematic. Our approach integrates chemical properties, drug-likeness 
measures and target-based properties of a molecule into a random forest model to predict 
whether the drug is likely to be a member to fail clinical trials for toxicity reasons.  
 
Figure 3.2. Distributions of select (a) chemical features, and (b) target-based model 
features. The Kolmogorov-Smirnov D statistic and p-value are shown for the comparison of 
failed toxic clinical trial (FTT) drugs (red) and FDA approved drugs (blue). 
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based features represent the network connectivity of the target, with gene degree 
and betweenness features, computed using an aggregated gene-gene 
interaction network (Aksoy et al., 2013; Das et al., 2012; Khurana et al., 2013), 
and a feature that represents the loss of function mutation frequency in the target 
gene, extracted from the Exome Aggregation Consortium 
(ExAC) database(Exome Aggregation Consortium (ExAC)). Like the chemical 
properties, we found that some of these target-based features also were able to 
weakly but significantly discriminate between FDA approved drugs and FTT 
drugs (Figure 3.2B). Not surprisingly, many of the features within the target-
based or the chemical category were highly correlated with each other. Since we 
found the target expression values to be highly correlated, principle component 
analysis was applied to all target expression values in order to reduce the feature 
dimensionality. In place of the raw expression values, the first three principle 
components were instead used. However there was little correlation between the 
two classes of features (maximum Pearson correlation of r=0.1942). Thus the 
target-based features add information independent of the chemical features into 
the model. 
The approach was tested by performing 10-fold cross validation on a set of 784 
FDA approved drugs with known targets and the drugs associated with 100 FTT 
that had at least one annotated target and known chemical structure. We found 
that PrOCTOR had significant predictive performance, with an area under the 
receiver operator curve (AUC) of 0.8263 (Figure 3.3A). At the optimal point of 
the curve the method achieved an accuracy (ACC) of 0.7529, with both high 
sensitivity (true positive rate (TPR) of 0.7544), and high specificity (true negative 
rate (TNR) of 0.7410). By comparison, on this same dataset the Ro5 and Ghose 
rules had a TPR of 0.8030 and 0.6468, respectively, and a TNR of 0.27 and 0.46 
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respectively. Application of the Veber method achieved a TPR of 0.2465, and a 
TNR of 0.92. (Figure 3.3A). The ROC curve of both the unweighted and 
weighted versions of the QED method fell significantly below that of PrOCTOR’s 
ROC curve (AUC=0.581, p<2.2e-16, Wilcoxon signed rank test), indicating that 
PrOCTOR is able to better distinguish the FTT and approved drug classes. 
Furthermore, PrOCTOR’s approval probability allows for the separation of the 
drugs of the FFT and FDA approved classes (D=0.5343, p< 2.2e-16, 
Kolmogorov-Smirnov test) (Figure 3.3B) on a continuous scale.  
We further assessed the approach by applying PrOCTOR to drugs that are 
approved in Europe (EMA-Approved) or in Japan (JP17) but not annotated as 
being FDA approved in our dataset. When compared to the FTT drugs in our 
training set, we found that EMA-Approved (p<2.2e-16, Mann–Whitney U Test) 
and JP17 drugs (p= 9.84e-14, Mann–Whitney U Test) were predicted to be 
significantly safer and had a similar distribution of PrOCTOR scores to the class 
of FDA Approved Drugs (Figure 3.3C). 
Next, we applied PrOCTOR to 3,236 drugs that were in DrugBank and not in our 
training set. We found that the predicted toxic drugs had significantly more 
frequent reports of serious adverse events, such as death and renal failure, than 
predicted safe drugs in the openFDA resource of drug adverse events 
(https://open.fda.gov) (Figure 3.3D). Furthermore, we found that safe predictions 
were enriched for classes of drugs that are known to be relatively safe, such as 
antidepressants, stimulants, and serotonin-related drugs. In comparison, toxic 
predictions were enriched for known toxic classes of drugs, such as 
immunosuppressive agents and antineoplastic agents. 
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Figure 3. Benchmarking Model performance. (a) Receiver operating characteristic (ROC) 
curves for PrOCTOR, three drug-likeness rules (Ro5, Veber, Ghose) and both the weighted 
and unweighted QED metrics. (b) PrOCTOR scores and the Q.E.D. metric for approved and 
failed toxic clinical trial (FTT) drugs. (c) PrOCTOR scores for the FDA approved and FTT 
drugs in the training set, as well as EMA-Approved and Japanese-Approved (JP17) drugs 
after removal of FDA approved drugs. Statistical significance was assessed for FDA, EMA, 
and JP17 vs FTT drugs using the Mann-Whitney U Test. (d) Reported frequencies, 
normalized to the most frequently reported adverse event, in the openFDA database for 
predicted toxic (red, score<-1) and predicted safe drugs from the DrugBank dataset. (e) The 
top three molecules predicted by PrOCTOR as most likely to be FDA approved are 
phenindamine, carbinoxamine, and chlorcyclizine. (f) The three molecules predicted by 
PrOCTOR as most likely to fail clinical trials for toxicity reasons are docetaxel, bortezomib, 
and rosiglitazone. 
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We also applied our approach to 137 drugs annotated as most-DILI-concern and 
65 drugs of no-DILI-concern by the FDA. We found that the most-DILI-concern 
drugs had 1.5-fold higher odds of being classified as toxic by PrOCTOR than the 
no-DILI-concern drugs. More generally, the most-DILI-concern drugs had higher 
PrOCTOR scores than the no-DILI-concern drugs (p= 0.0005, Mann–Whitney U 
Test). This suggests that our model is able to generalize beyond the training set. 
Identification of FDA drugs with increased likelihood of toxicity events 
Next we looked to evaluate the predictions of our approach by analyzing 
PrOCTOR’s predictions for FDA approved drugs. A PrOCTOR score expressing 
the log2(odds of approval) was calculated taking the log2 of the ratio of the 
PrOCTOR-predicted probability of approval to the probability of failure. 
The three molecules identified by PrOCTOR as most likely to receive FDA 
approval were phenindamine, carbinoxamine, and chlorcyclizine (Figure 3.3E). 
All three of these drugs are FDA approved antihistamines with highly tolerable 
side effects. Interestingly, all three of these drugs pass the Ro5 but have 
relatively low QED values (0.311, 0.242, and 0.499 respectively).  
The three molecules with the worst PrOCTOR score and thus predicted as most 
likely to fail clinical trials for toxicity reasons were docetaxel, bortezomib, and 
rosiglitazone (Figure 3.3F). Of note, all are FDA approved drugs that have been 
associated with serious toxicity events. Docetaxel is a chemotherapy agent used 
to treat a number of cancers(Massacesi et al., 2004; Puisset et al., 2007). The 
most frequent adverse event associated with docetaxel is neutropenia, a 
potentially life threatening event that often results in delay of treatment(Puisset et 
al., 2007). It also fails the Ro5 and has an extremely low QED of 0.147, 
suggesting that this prediction is consistent with other drug screening methods. 
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Bortezomib is a proteasome inhibitor used for treatment of relapse multiple 
myeloma that has a moderate QED value of 0.476 and passes the Ro5. While it 
was FDA approved due to its significant antitumor activity, it has been associated 
with frequent adverse events, such as peripheral neuropathy, that are thought to 
in part be due to nonproteasomal targets (Arastu-Kapur et al., 2011). 
Rosiglitazone is an antidiabetic drug that also passes the Ro5 and has a high 
QED value of 0.825. However it has been linked with an elevated risk of heart 
attack(Nissen et al., 2007) and consequently was withdrawn from the market in 
Europe in 2010(Blind et al., 2011). This suggests that existing methods were not 
necessarily able to foresee the adverse events associated with these latter two 
compounds.  
These compounds bring to attention the importance of context when considering 
toxicity events. In general, more frequent and serious side effects will be 
acceptable for drugs that are used to treat severe and otherwise untreatable 
conditions, such as cancer. This is an important consideration to keep in mind 
when determining acceptable score ranges in drug development. Additionally, it 
highlights the shortcomings of rule-based methods, which are unable to quantify 
the extent to which a drug may have undesirable characteristics since a molecule 
that just barely fails one requirement is equivalent to one that substantially fails 
all requirements. 
We further assessed what insights the predictions from PrOCTOR can offer 
regarding toxic effects using the SIDER side effect resource database (Kuhn et 
al., 2010). We hypothesized that drugs with better PrOCTOR scores would have 
less frequent severe side effects reported due to their more tolerable toxicity 
profiles. We first compared all drugs predicted to be approved by PrOCTOR (via 
cross-validation), including those misclassified, to those predicted to be of the 
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FTT class. We found that the predicted FTT drugs had significantly more 
frequent severe side effects, such as neutropenia (37.3% vs 14.3%, p=1.78x10-7, 
Fisher-Exact test) (Figure 3.4A). When comparing the drugs with the top 10% 
best PrOCTOR scores to those within the bottom 10%, this distinction was even 
greater with severe toxic events, such as neutropenia (54.8% vs 13.4%, 
p=1.72x10-6, Fisher-Exact test) and pleural effusion (47.6% vs 5.2%, p=2.59x10-
7, Fisher-Exact test), occurring far more frequently in the predicted FTT class.  
Furthermore, we found that these severe side effects were significantly 
negatively correlated with the PrOCTOR score. For example, the spearman’s 
correlation coefficient of the binned pleural effusion frequency against the 
PrOCTOR score was ρ=−0.9792 (Figure 3.4B) and for neutropenia was 
ρ=−0.9613 (Figure 3.4C). In comparison, the frequent side effect of dizziness 
still occurred more frequently in the predicted toxic drugs but had a much weaker 
correlation of ρ=−0.5070. Thus the predictions of PrOCTOR are consistent with 
reported adverse events, with the PrOCTOR score negatively correlating with the 
reported severe side effects that would ultimately contribute to a drug’s success 
in clinical trials. 
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Figure 3.4. Side Effects. (a) Adverse events that occur more frequently in predicted failed 
toxic clinical trial (FTT) drugs compared to predicted approved drugs. (b) Binned frequency 
of pleural effusion across PrOCTOR score bins. (c) Binned frequency of neutropenia across 
PrOCTOR score bins.	
 
Model reveals insights about how various properties can contribute to or 
help avert toxicity 
We evaluated what insights PrOCTOR can offer about successful drugs. A 
feature importance analysis showed that both the chemical and target-based 
features contribute significantly to the performance of the PrOCTOR algorithm. 
The first expression principle component, QED metric, polar surface area, and 
the drug target’s network connectivity emerged as the four most important 
features (Figure 3.5A-B), thus target-based features were identified as highly 
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important features for predicting toxicity. Using target-based features alone, 
PrOCTOR achieved a significant predictive performance (ACC=0.7115). Our 
approach relies on existent annotation of drug targets to calculate these features. 
However this information is often not available during the drug development 
stage. We found that our method is robust to removal of targets (Figure 3.5C) 
and additionally maintains a significant predictive performance (ACC= 0.6708) in 
absence of known target information. However PrOCTOR’s performance remains 
strongest when including both the chemical and target-based features 
(ACC=0.7529). 
We next investigated the relationships between the features in the model. We 
found that certain combinations of uncorrelated features provided greater 
discriminative power. For example, Bickerton et al. (Bickerton et al., 2012) 
reported that the QED approach outperformed other drug-likeness methods 
when the threshold was set at 0.35. We found that 75% of drugs with QED<0.35 
were approved. However when high testis expression (FPKM>10) was added 
into consideration, 88.5% of FTT drugs were accurately be classified. 
Additionally, tissue selectivity is a useful consideration in determining potential 
toxic effects. We hypothesize that this may be due to some tissue-specific toxicity 
events being associated with the drug target’s expression in normal tissue.  We 
found that 84% (38/45) of drugs with high molecular weight (MW>500) but low 
general tissue expression (PC1< -2) were FDA approved. Thus if a gene appears 
to be a promising target for mechanistic reasons while appearing ill-suited due to 
high global expression profiles, it still may remain a viable candidate given that 
certain molecular properties are satisfied. 
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Figure 3.5. Feature Importance and Model Robustness. Mean decrease Gini coefficient 
observed upon feature removal for the top 20 features (a) with all individual expression 
features and (b) with top 3 expression principle components instead of individual expression 
features. (c) Violin plots showing the range of AUC, accuracy, sensitivity and specificity for 0-
5 targets removed.  
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DISCUSSION 
Drug-likeness approaches, as first proposed by Lipinski almost two decades ago, 
have become a key tool for the pre-selection of compounds that are likely to have 
manageable toxicity in clinical studies. However all these methods consider only 
the molecular properties of the drug itself. We have proposed a data-driven 
approach (PrOCTOR) for predicting likelihood of toxic events in clinical trials that 
moves beyond existing drug likeness rules and measures by not only considering 
the chemical properties of a molecule, but also the properties of the drug’s target. 
When trained on failed clinical trials and FDA approved drugs, the PrOCTOR 
score performs at high accuracy, specificity and sensitivity. Furthermore, the 
PrOCTOR score strongly correlates with reported severe adverse events. 
While phase I trials are designed to investigate safety, drugs can fail at any stage 
for toxicity reasons and additionally can fail phase I trails for non-safety reasons. 
Lipinski’s Ro5 was derived using the set drugs that had succeeded to phase II 
trials, under the assumption that undesirable drugs would have been eliminated 
in Phase I (Lipinski et al., 1997). However it has been observed that a substantial 
number of drugs fail in Phase II trials and beyond for safety reasons (Ledford, 
2011). Additionally many of the drug-likeness measures were developed using 
larger representative datasets in place of clinical trial data(Bickerton et al., 2012). 
While these methods are important, they are focused on subtly different 
problems such as bioavailability. We have shown above that these approaches 
are not able to sufficiently capture clinical trial safety. There have been a number 
of other methods that have been developed to predict toxicity events as well. A 
recent DREAM Challenge focused on predicting cytotoxicity in lymphoblastoid 
cell lines, however primarily focused on environmental toxins(Eduati et al., 2015). 
Similarly, the EPA’s extensive ToxCast dataset is covered predominantly by non-
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therapeutic chemicals(USEPA, 2016). Other toxicity prediction methods, such as 
those in AMBIT, have been developed to address other toxicity-based questions, 
including model organism and tissue-specific toxicities(Jeliazkova et al., 2011). 
QSAR models are also frequently used for toxicity prediction. However they have 
generally been applied to the prediction of specific toxicity endpoints, such as 
drug LD50 values, tissue-specific toxicity events or for the estimation of maximum 
tolerated dose levels (Patlewicz et al., 2016). Finally, PK/PD models are highly 
valuable tools for identifying toxicological properties of drugs preclinically, but 
must be independently constructed for every drug and thus would benefit from 
more high-throughput methods for toxicity prediction(Sahota et al., 2016). 
Consequently, we selected the set of drugs that failed any phase of clinical trials 
for toxicity reasons to develop our approach.  
We have also only addressed the issue of general clinical trial toxicity. However 
some indications, such as cancers, have more critical needs and consequently 
allow for higher toxicity levels. As a result, our model may predict some 
promising anti-cancer drugs to have unmanageable toxicity levels. Since 
PrOCTOR outputs a score, instead of just a prediction, a different threshold for 
allowable toxicity may be considered for different indications. A preliminary 
testing of this idea on cancer-only drugs with cancer type added as a feature 
demonstrated improved predictive power on this subset of drugs (ACC=0.74, 
AUC=0.80). However given the small sample size of this training set (n=89), this 
cancer-specific model is not optimal at this time. Additionally many new therapies 
are currently being developed to target specific isoforms and mutations. While 
our model is not currently accounting for these specific targets, it can 
straightforwardly be adapted using publicly available or user-provided target-
based information. There are also areas in which PrOCTOR could be further 
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improved such that leads to better predictive capacities. The use of 3D 
fingerprinting methods may allow for the structural features to be better 
represented. Co-expression networks from the GTEx data may also be useful 
features, as they may provide a stronger biological signal. Biological interaction 
networks are generally incomplete and also vary between cellular contexts and 
populations, which may limit the power of the network metrics. Finally, our 
method is largely dependent on existing target annotation for drugs, which is 
generally incomplete. Thus we will likely benefit from advancements in drug 
target identification. 
Furthermore over two-thirds of clinical trials fail for other reasons, including 
efficacy, strategic and financial reasons (Ledford, 2011). The problem of efficacy 
is a highly complex issue, since each drug must demonstrate improvement over 
existing drugs in addition proving a context-specific efficacy. Thus while this 
problem remains important, it is not likely to be tractable using this style of 
approach. 
Our approach has the potential to impact the preclinical drug development 
pipeline by quantifying how likely a given compound is to have manageable 
toxicity in clinical trials. In order to facilitate interaction with and application of our 
model, we have developed an interactive tool that we have made available on 
github (https://github.com/kgayvert/PrOCTOR). PrOCTOR may also help flag 
drugs for increased post-approval surveillance of adverse effects and toxicity. 
Perhaps even more importantly, the model will help design better drugs by 
providing insights about how various chemical and target-based properties can 
contribute to or help avert toxicity. 
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CHAPTER FOUR 
A COMPUTATIONAL APPROACH FOR IDENTIFYING SYNERGISTIC DRUG 
COMBINATIONS* 
 
PREAMBLE 
This chapter consists of a paper that was published in PLoS Computational 
Biology in January 2017. The method was conceived in partnership with Dr. 
Olivier Elemento. I implemented the method and subsequent computational 
analyses. The experimental validation was performed by Omar Aly. The Stern 
and Bosenberg labs generated the data and contributed the expertise to results 
interpretation (D.F.S., M.W.B., J.P.). 
INTRODUCTION 
Targeted therapies designed to specifically target molecules involved in 
carcinogenesis have achieved remarkable antitumor efficacy. In melanoma, over 
half of patients are reported to harbor activating mutations in the BRAF oncogene 
(Curtin et al., 2005; Held et al., 2013). BRAF inhibitors, such as vemurafenib, 
have been developed to selectively kill mutant BRAF positive cells (Chapman et 
al., 2011). Patients initially exhibited significant responses to these drugs, with 
48% responding to vemurafenib in phase 1 and 2 clinical trials, however 
resistance developed within months (Chapman et al., 2011).  
Combination therapy has been proposed for preventing and overcoming 
resistance. This is thought to be a promising option because resistance to the 
																																																						
*	Gayvert	KM,	Aly	O,	Platt	J,	Bosenberg	MW,	Stern	DF,	Elemento	O.	A	Computational	
Approach	for	Identifying	Synergistic	Drug	Combinations.	PLoS	Comput	Biol.	
2017;13(1):e1005308.	
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combinatorial therapy would require either acquisition of multiple mutations 
rapidly (Fitzgerald et al., 2006) or an individual mutation that is able to bypass 
both drugs (Komarova et al., 2013), both of which are low probability events. 
Additional goals of combination therapy are to lower drug dosage levels in order 
to reduce the frequency and severity of adverse events and to achieve enhanced 
effectiveness through either drug additivity or synergy (Fitzgerald et al., 2006).  
Drug synergy can occur through a variety of mechanisms. These include 
enhancement of bioavailability, through inhibition of parallel pathways(Cokol et 
al., 2011), and chemosensitization, in which the first compound primes the cells 
to be sensitive to the second drug(Bansal et al., 2014). Synergy is generally 
quantified through either effect based or dose-effect based methodologies. 
Effect-based methods compare the independent effects of drugs, while dose-
effect based methods assume nonlinear individual dose–effect curves(Foucquier 
et al., 2015). The most popular effect based method is the Bliss Independence 
model, which assumes that drugs act independently and the expected additive 
effect is based on the common probabilistic independence formula(Foucquier et 
al., 2015). However limitations of this approach include that it does not account 
for nonlinearity in dose response curves (Yeh et al., 2009) and its independence 
assumption. Since the mechanism of action for many drugs remain unknown, the 
validity of the independence assumption is often not met (Foucquier et al., 2015). 
A popular dose-effect based method is the Chou-Talalay Combination Index (CI), 
which is a median-effect equation based on the “mass-action law”(Chou, 2010). 
A major limitation of the Chou-Talalay method is its dependence on accurate and 
well-defined dose-effect curves, which are not always available(Foucquier et al., 
2015). 
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Given the poor prognosis of BRAF melanoma and the rapid rate at which 
resistance develops and tumors progress, there is an urgent need to identify 
suitable combinations. The first drug combination for treatment of advanced 
melanoma was approved in January 2014 and involved the BRAF inhibitor, 
dabrafenib, and the MEK inhibitor trametinib. This combination was pursued due 
to the great response rates of the individual drugs with the goal of preventing 
drug resistance. Indeed, it has been observed that the combination delays the 
development of resistance and prolongs progression free and overall 
survival(Robert et al., 2015). However it is certain that many more combinations 
exist and are not yet known. Additionally, a subset of patients that were treated 
with the combination of dabrafenib and trametinib have developed resistance to 
this combination therapy(Robert et al., 2015). 
Existing methods that have been developed to predict synergistic combinations 
have generally relied on mechanistic insights. However they have been applied 
only in limited specific contexts, such as in B cells (Bansal et al., 2014). 
Furthermore numerous studies have shown that synergy is very dependent on 
context (Bansal et al., 2014; Cokol et al., 2011; Held et al., 2013). This makes it 
difficult to utilize any prior knowledge about synergistic drug combinations from 
other different cancers or genotypes. A systematic method for identifying optimal 
combinations would therefore be highly impactful. Here we propose a 
computational approach utilizing existing high-throughput drug screen data to 
help identify other combinations that are both synergistic and effective in the 
context of mutant BRAF melanomas. 
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RESULTS 
Single Dose Response Predictive of Combinatorial Synergy and 
Effectiveness 
We set out to determine whether combination efficacy and synergy could be 
predicted from single agent efficacies. Previous computational approaches to 
drug combinations have shown that the dose response curves of single agents 
exhibit predictive power for identifying synergistic combinations (Bansal et al., 
2014). To further investigate this, we utilized a high-throughput drug screen that 
was performed by Held et al. (Held et al., 2013). In this study, the response of 
150 single agents and a large combinatorial drug screen involving 40 drugs were 
experimentally tested across mutant BRAF, mutant RAS, and wild-type BRAF 
and RAS (WT) cell lines. For each drug pair, we derived a feature set that 
consisted of the mean and difference of the single agent dose response in each 
tested cell line. The single agent dose response was represented as the percent 
of concentration required to inhibit 50% of growth inhibition (GI50). Altogether, this 
resulted in a total of 54 total features representing the similarity of a drug pair’s 
efficacies in 27 melanoma cell lines (Figure 4.1).  
The results of the combinatorial drug screen were used to identify genotype-
selective and synergistic combinations. Genotype-selective combinations were 
defined to be those that yielded an average 15% or greater growth inhibition 
exclusively in the genotypic group and achieved at least 50% growth inhibition 
within the genotypic group. We further defined a general effective combination to 
be one that achieved at least 70% growth inhibition. Finally we computed 
synergy labels for each combination using the Chou-Talalay synergy combination 
index  (CI) metric. We decided to use the Chou-Talalay approach because the 
Chou- 
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Figure 4.1 – Feature construction schematic. For each drug pair, we combined the drug 
pair’s efficacies by taking the mean (μ) and difference (Δ) in 27 mutant BRAF (red), mutant 
RAS (green) and WT (blue) melanoma cell lines. 
Table 1 - Model Performance 
 AUC Accuracy Sensitivity Specificity 
BRAF-specific effectiveness 0.8809 0.8230 0.6911 0.8894 
General BRAF-effectiveness 0.8630 0.7800 0.6818 0.8418 
BRAF synergy 0.8683 0.8213 0.4196 0.9494 
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Talalay CI was provided in the original dataset and furthermore the mechanism 
for many drugs in the training set is unknown. We defined a synergistic 
combination to be a pair of drugs that demonstrated CI < -1 at any concentration 
level. Overall, the combinatorial screen helped identify 248 BRAF-selective and 
161 synergistic combinations. 
We then trained random forest models (Breiman, 2001a) on 780 drug 
combinations for each of the outcomes described above in context of BRAF and 
RAS melanomas (Figure 4.2A). We evaluated our approach using 10-fold cross-
validation and found that our model exhibits significant power (Table 1) for 
predicting both synergy (AUC=0.8663, Accuracy=0.8213) and genotype-selective 
efficacy (AUC=0.8809, Accuracy=0.8230) in context of BRAF melanomas 
(Figure 4.2B). Importantly both models maintained high specificity rates (0.9494 
and 0.8894 for synergy and effectiveness respectively) which suggests that there 
would be few false leads. As a control to identify limitations of our approach, we 
evaluated our model by making predictions for “sham combinations”, which were 
cases in which a drug is combined with itself. We found that 98% (147/150) of 
the sham combinations were predicted to not be synergistic. We also found that 
both the effectiveness and synergy models exhibit significant robustness (Figure 
4.2C). At 25% of the original number of combinations used in the training set, the 
BRAF-specific effectiveness approach maintained 77.56% accuracy, 89.27% 
specificity, and 54.91% sensitivity. This suggests that fewer combination testing 
could be performed while maintaining strong confidence in the positive 
predictions, given that the specificity remains high. Since high-throughput 
screens require significant resources and time, this type of approach could prove 
to be valuable in screening the larger space of drug combinatorial pairs given 
that a suitable representative set is chosen for initial testing. 
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Figure 4.2 – Method schematic and Evaluation of individual model performance.  
A Our approach integrates a large single drug screen of 150 drugs with a combinatorial 
drug screen, which tested 780 combinations of 40 unique drugs. This was used to train a 
random forest model that predicts synergy and genotype-selective efficacy for untested 
drug combinations. 
B  Receiver operating characteristic (ROC) curves for 10-fold cross-validation of the BRAF-
specific effectiveness (top) and synergy (bottom) models. 
C The effect of randomly removing samples on model accuracy, sensitivity and specificity. 
At 25% of the original number of combinations was used to train the model, the approach 
maintained 77.56% accuracy, 89.27% specificity, and 54.91% sensitivity. 
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The single agent screens performed by Held et al (Held et al., 2013) included 
110 drugs that were not tested in the combinatorial screen, so we applied our 
approach to the 10,395 additional untested combinations. We predicted 842 
combinations to be synergistic, 890 to be effective, and 304 to be both effective 
and synergistic in context of mutant BRAF melanoma. We found that our 
predictions had noticeable patterns of synergy and effectiveness (Figure 4.3A). 
Predicted synergistic combinations involved drugs that had varying levels of 
efficacy across the different mutant BRAF cell lines, with synergistic 
combinations demonstrating a trend towards lower correlation of GI50 values 
across the mutant BRAF cell lines (p=0.07929, Kolmogorov-Smirnov Test). In 
contrast, combinations involving drugs with similar efficacy profiles across the 
different cell lines were generally predicted to be non-synergistic. Thus it appears 
that our approach drew its strength from the large number of tested cell lines.  
To further evaluate our approach, we compared these predictions to an 
independent high-throughput screen that tested 5,778 combinations involving 
108 drugs at two concentration levels, high and low(Friedman et al., 2015). Our 
prediction dataset contained 274 combinations that overlapped with this 
independent dataset. We found that our predicted effective combinations had a 
significantly higher growth inhibition levels than our predicted non-effective 
combinations (p=0.002602, Student’s t Test) (Figure 4.3B). 
Experimental Validation of Novel Synergistic and Effective Combinations 
for BRAF Melanoma  
We next identified a subset of 7 drugs with a diverse set of predictions (Figure 
4.3C). These drugs included a BRAF inhibitor (PLX4720), a statin (Simvastatin), 
two chemotherapies (Doxorubicin, Paclitaxel), and three drugs of other various 
mechanisms (Fak Inhibitor 14, Gefitinib, 17AAG). We tested each of these drugs  
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Figure 4.3 – Predictions for Previously Untested Combinations. (a) We applied our 
trained model to make predictions for 10,395 additional untested combinations. (b) 
Comparison of growth inhibition levels, as reported by Friedman et al., for 274 predicted 
effective or ineffective drug combinations. (c) We focused on a subset of 7 drugs to 
experimentally follow-up on our predictions for previously untested combinations. 
  53 
Table 2 - Experimental Validation 
 Accuracy Sensitivity 
(TPR) 
Specificity 
(TNR) 
FDR 
BRAF effectiveness 0.73 0.71 0.75 0.125 
BRAF synergy 0.64 0.67 0.5 0.14 
 
both alone and in combination in the mutant BRAF melanoma cell line MALME-
3M at low, medium, and high concentrations, estimated from their GI10, GI25, and 
GI50 values respectively. 
We found that our method continued to demonstrate significant predictive power 
when tested on cell lines that were independent of the original training set 
(Figure 4.4A, Table 2). We validated 82% and 64% of the effectiveness (Figure 
4.4B) and synergy predictions (Figure 4.4C) respectively. Importantly, we also 
found that the false discovery rates (FDR) for both synergy and effectiveness 
predictions remained relatively low (14.3% for synergy, 12.5% for effectiveness) 
despite being tested in a different setting. 
BRAF inhibitors are of high interest for treating BRAF-mutant melanomas due to 
their selectivity and effectiveness. To further investigate the efficacy and synergy 
of combinations involving PLX4720, we performed more extensive experiments 
for predicted synergistic and non-synergistic drug partners. PLX4720 was 
predicted to be synergistic with FAK inhibitor 14 and non-synergistic with 17AAG, 
a Hsp90 inhibitor. Instead we found both combinations to be synergistic when 
tested across the 9 combinations of varying concentrations. Interestingly, we 
observed that while 17AAG appeared to be synergistic when combined with 
PLX4720 held at a constant rate, PLX4720 itself was not synergistic when 
17AAG was held constant (Figure 4.5A). However PLX4720 was very 
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synergistic when combined with a constant dosage of FAK Inhibitor 14 (Figure 
4.5B), consistent with the synergy prediction. Additionally we observed that 
PLX4720 was highly synergistic with paclitaxel. This combination represents a 
potentially impactful combination since paclitaxel and vemurafenib are both used 
in clinical trials for the treatment of melanoma (Chapman et al., 2011; Pflugfelder 
et al., 2011). Furthermore previous reports have suggested that the combination 
of BRAF inhibitors with paclitaxel represents a promising therapeutic approach 
for overcoming resistance in BRAF melanomas (Thang et al., 2015). 
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Figure 4.4 – Experimental Validation of Predicted BRAF Effective and Synergistic 
Combinations.  
A We selected a set of 11 combinations involving 7 drugs with a diverse set of predictions 
for experimental validation. These included traditional chemotherapeutic agents 
(doxorubicin, paclitaxel), targeted agents (PLX4720, gefitinib, FAK Inhibitor 14), a statin 
(simvastatin), and an antitumor antibiotic (17AAG). 
B  Each drug was tested in combination at medium, and high concentrations, estimated 
from their GI10, GI25, and GI50 values respectively. The observed growth inhibition levels 
for all dosage level combinations involving each tested drug combination are shown in 
violin plots. Violin plots that are colored navy blue are those whose third quantile values 
where 70% or greater. The predictions for each combination are shown below the plot, 
with dark blue representing an effective prediction and grey representing an ineffective 
prediction. 
C For each tested drug combination, the Chou-Talalay synergy scores were calculated. The 
observed synergy scores for all dosage level combinations involving each tested drug 
combination are shown in violin plots. The predictions for each combination are shown 
below the plot, with green representing a synergy prediction and red representing a non-
synergy prediction. 
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Figure 4.5 – Identification of Synergistic Combinations involving the BRAF Inhibitor 
PLX4720. 
A The observed growth inhibition levels for PLX4720 alone (blue) 17AAG alone (red), 
PLX4720 varying while 17AAG held constant at 1uM (navy blue), and 17AAG varying 
while PLX4720 held constant at 1 uM (dark red). 
B  The observed growth inhibition levels for PLX4720 alone (blue) FAK Inhibitor 14 alone 
(red), PLX4720 varying while FAK Inhibitor 14 held constant at 0.1uM (navy blue), and 
FAK Inhibitor 14 varying while PLX4720 held constant at 0.1 uM (dark red). 
 
 
DISCUSSION 
We found that drug synergy and combinatorial effectiveness can be predicted 
from a relatively small subset of combinations based only upon single drug 
efficacies. We experimentally validated novel predictions involving 7 drugs in a 
BRAF mutant cell line with FDR<0.15. This analysis included compounds that 
span a variety of drug classes, including targeted therapies and chemotherapies. 
Additionally, an analysis of the model robustness suggested that it is possible to 
confidently make these predictions with even smaller subsets, while maintaining 
significant confidence in the positive predictions. We note that while we propose 
that a smaller training set can be used to infer these combinations, it is critical to 
retain a distinctive and representative set of drug combinations in the training set. 
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The classification errors, particularly those involving synergy predictions, may be 
due in part to varying genetic conditions since the combinations were tested in a 
different cell line than the original training set. This is supported by one 
combination that was tested both in our experiments and in the larger 
combinatorial drug screen that had inconsistent synergy and effectiveness levels. 
The combination of Fak Inhibitor 14 and gefitinib was found to be synergistic in 
the combinatorial screen, however we found it to be non-synergistic in our 
experiments. Consequently we believe that our false discovery rate would have 
been even lower if we had tested the combinations in the same setting that was 
used to generate the training set. However the validation of the majority of our 
predictions across slightly variable contexts is highly relevant for the treatment of 
patient cancers, in which the treated patient populations involve different 
individuals and thus have slightly different genomic profiles than the population 
under which the therapy was conceived. Additionally we would like to emphasize 
that any effectiveness (or synergy) predictions that our model makes are in the 
context of mutant BRAF cell lines. While we hope that some of these findings 
may be translatable to human patients, many other factors must first be 
considered. 
It is important to note that we did not consider maximum tolerated doses (MTD) 
in our analysis. A retrospective analysis revealed that there were two drugs 
included in our analysis that were tested at levels above MTD for humans: 
Obatoclax and Tamoxifen. Additionally there are many drugs included in the 
study do not have known MTD. This is because these drugs are experimental 
and thus have not yet had this evaluated in clinical trials(Marshall, 2012). While 
we do not believe that this biases the model, it does highlight the importance of 
clear model interpretation. In particular, we observed in our experiments that 
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synergy generally did not occur at high dosage levels (Figure 4.5), which further 
suggests that the model would not be biased by including drugs that were tested 
above MTD. Importantly our approach allows subsequent experimental studies to 
be prioritized on promising combinations, which can be focused on more 
clinically relevant information such as MTD. 
The use of synergistic drug combinations has the potential to help prevent and 
overcome drug resistance. It is hypothesized that the application of drug 
combinations with initial treatment lower the odds of resistance occurring 
because it requires multiple mutations to bypass both drugs, which is a lower 
probability event than each drug individually(Fitzgerald et al., 2006; Komarova et 
al., 2013). This could be particularly impactful for combinations involving BRAF 
inhibitors, which individually have demonstrated remarkable responses in 
patients but suffer from the rapid development of resistance(Chapman et al., 
2011). To further explore how models could be used to identify drug 
combinations that overcome drug resistance, we used our training set to derive a 
set of 24 effective and 12 non-effective combinations involving vemurafenib in 
resistant cell lines. We applied the framework of our approach to this small 
dataset and found that there is an underlying signal for predicting combinations 
that overcome resistance (AUC=0.677, Accuracy=0.697). Thus approaches such 
as ours may be applicable both to directly predicting combinations that overcome 
resistance, as well as predicting combinations that may help prevent resistance 
from developing. 
Existing methods have previously found that the inclusion of features 
representing the biological mechanisms of the drug have been most 
successful(Bansal et al., 2014). However this information is often not available. 
Indeed only 50% (20/40) of the drugs in our training set have information about 
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the drug’s target. Thus our method would likely improve as this type of 
information becomes more widely available enough to include in the model. 
However our model was able to exhibit significant predictive power despite this 
information not being available. We hypothesize that this was due to the large 
number of cell lines that each single agent was tested in. We found that generally 
the predicted synergistic combinations involved drugs that had varied single 
agent efficacies across the different mutant BRAF cell lines. 
While we have trained and tested our approach in the context of BRAF mutant 
melanoma, the approach itself is applicable to other types of cancers. As 
additional large combinatorial screens become available, this methodology could 
prove to be impactful for the identification of drug synergy within the larger 
universe of possible drug combinations. 
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PERSPECTIVE 
 
In recent years, enormous amounts of biomedical data has been generated and 
collected. These span from genomics to drug to other healthcare-related 
datasets. In genomics, large consortiums have focused on establishing large 
collections of patient sequencing data (eg. TCGA, 1000 Genomes, GTEx) and 
have identified and analyzed patterns that emerge (eg. EXaC, COSMIC). Similar 
efforts have been put forward in collecting information about drugs, such as 
characterizing their targets (DrugBank), general structure and properties 
(PubChem, CHEMBL), and their biological effects (NCI-DTP, CMAP, LINCS). 
Additional relevant information exists in other healthcare records, such as 
Electronic Medical Records (EMR/EHR), adverse event reports (FAERS), and 
clinical trial results.  
The integration of these disparate datasets through machine learning and other 
quantitative methods remains largely unexplored, which creates an opportunity to 
answer interesting and important questions. Addressing inefficiencies in the drug 
development pipeline is one critical application with large potential. From drug 
repositioning to understanding drug mechanisms, there are many areas of the 
drug development process in which computational and data-driven methods 
could provide powerful insights. There is also potential in using these data to 
better understand disease and patient outcomes.  
However there also remain many important challenges to working with and 
integrating these different data types. Pipelines for generating and analyzing 
genomics datasets are constantly evolving and vary across the field, which limits 
the extent to which different genomics datasets can be combined to make more 
powerful conclusions. In the drug space, inconsistent annotation and naming 
  61 
nomenclature presents a similar problem. Furthermore there is a lack of clear 
and consistent definitions of clinical outcomes across healthcare datasets. The 
system of medical ontology used in health records varies between hospitals. 
Reports of clinical trial outcomes are often incomplete, with only 13.4% and 
38.3% of trial results reported within 1 and 5 years respectively after trial 
completion (Anderson  et al., 2015). Finally patient privacy concerns add an 
additional barrier to acquiring and leveraging datasets. 
Addressing these challenges require large-scale efforts to be put into place. 
Fortunately many such efforts are already underway. In New York State and City, 
there is a public initiative to develop a comprehensive health information 
infrastructure with the goals of empowering better data-driven population health 
surveillance. In genomics, it is often mandated that data generated using grants 
or presented in publications be deposited in public repositories, including raw 
files, which will allow for better utilization of these datasets. However the problem 
of poor clinical trial reporting persists despite already existent federal mandates. 
This area of work, as well as many other federally funded projects, would benefit 
from both the mandate of data deposition and the follow-up of penalties for non-
compliance. Additionally, most compounds fail before they reach clinical trials 
and most data related to these compounds is not released outside the company 
in which it was developed. As a result, information that could be relevant for the 
purposes of repositioning and novel drug design is not utilized, further 
contributing to inefficiencies in the drug development process. 
Altogether there exists great promise for the integration of large, distinct 
biomedical datasets into machine learning and other quantitative models to 
answer important biological questions. 
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APPENDIX 
 
MATERIALS AND METHDOS - CRAFTT 
The CRAFTT approach 
CRAFTT requires two inputs for its predictions, ChIP-seq for a TF that is used to 
derive its target gene set and drug-induced expression profiles. The CRAFTT 
procedure (1) uses Gene Set Enrichment Analysis with the target gene set for a 
TF and drug-induced expression profiles as inputs to make predictions about 
what drugs modulate TF’s activity, and then (2) prioritizes predictions using 
network analysis. For the network analysis we compute a normalized path length 
score (NPL), in which we calculate the probability of observing the path length 
between the drug d and TF X (P(PL|d,X)) using 500 degree-preserving 
randomized networks(Gobbi et al., 2014). These steps are combined to generate 
a prediction score, which we term the modulation index (MI):  
MId,X =
NESd,X
P(PL | d,X)
 
where NPL = P(PL | d,X) = PLdxi ,Xxi < PLdg ,Xgi=1
500
∑
500
 
Statistical Analysis 
The statistical significance for each of our predictions was estimated according to 
the GSEA procedure (Subramanian et al., 2005). For the analysis of Electronic 
Medical Records (EMR), Kaplan-Meier Survival Analysis was performed on an 
age-adjusted cohort, using time to first diagnosis of prostate cancer as the end-
point in our study and excluding all patients with any prior diagnosis of cancer 
and cox proportional hazards test was used to assess significance. Statistical 
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analysis of RT-PCR, ChIP-PCR, cell invasion, and cell migration experiments 
was done in Prism using paired t test and n = 3 for each condition. 
All other statistical significance values were calculated in R. The permutation test 
(using 1000 random permutations) was used to assess significance of the 
enrichment of TF alterations in COSMIC and the enrichment of drug categories 
(e.g. HDAC inhibitors) within our predictions. The chi-squared test was used to 
compare the transcription factor enrichment to that of kinases. The significance 
for the enrichment of known interactions was calculated using the exact binomial 
test, comparing the enrichment of known pairs to the total percentage of drug-
pairs that were predicted. The Mann-Whitney test was used to assign 
significance to the network analysis and to the difference between GI50 
(concentration required to inhibit 50% of growth) values in WT and MT p53 cell 
lines.  
Experimental validation 
RWPE1, VCaP and DU145 were obtained from ATCC and maintained according 
to manufacture’s protocol. Isgogenic DU145 or RWPE1 +/-ERG cell lines were 
generated to over-express either truncated ERG as previously 
described(Rickman et al., 2010; Rickman et al., 2012). The PTEN-/-/ERGRosa26 
prostate cancer cells were derived from PTEN-/-/ERGRosa26 prostate tumors as 
previously described(Chen et al., 2013). For treatments the cells PBS and 
incubated with the appropriate media at the indicated drug or vehicle dose for 24 
or 48 hours.  
Cells were then analyzed using ChIP-PCR, quantitative RT-PCR (QRT-PCR) or 
invasion/migration assay. Quantitative RT-PCR, ChIP-PCR, cell invasion and 
migration assays were performed as previously described(Rickman et al., 2010; 
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Rickman et al., 2012). Each sample was run in triplicate. The amounts of target 
genes were calculated relative to the reference gene HMBS.  
 
MATERIALS AND METHDOS - PrOCTOR 
Clinical Trials Training Set 
We downloaded data from ClinicalTrials.gov from The Database for Aggregate 
Analysis of ClinicalTrials.gov (AACT)  41 39 38 38 38 34 34 34 34 34 34 34  10 10. To extract 
the names of the drugs associated with clinical trials that failed toxicity reasons, 
we identified any clinical trials that were annotated as “Terminated”, “Suspended” 
or “Withdrawn” and described as failing for toxicity reasons. The list of FDA 
approved drugs was obtained from the drug annotations within the DrugBank 4.0 
database (Law et al., 2014).  
Model Feature Derivation 
Chemical Features 
The structures (sdf format) were downloaded for all of the drugs in DrugBank. 
The molecular weight, polar surface area, hydrogen bond donor and acceptor 
counts, formal charge and number of rotatable bounds were extracted from the 
sdf file for each of these compounds. When that information was missing, it was 
filled in by querying PubChem or by computationally estimating these values 
using ChemmineR in R. The rule outcomes were then derived from these 
features. The QED values were computed using the author-released script. 
Network features 
We constructed the aggregated biological network by taking the union across 
multiple databases of gene-gene interactions. (Aksoy et al., 2013; Das et al., 
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2012; Khurana et al., 2013). The network degree of a gene was calculated as the 
number of gene neighbors that a particular gene has. For drug’s with multiple 
genes, the maximum value was take. The network betweenness for a particular 
gene (i.e. vertex) is defined as the number of shortest paths that travel through 
the vertex. This was calculated using the betweenness function in R’s igraph 
package(Csardi et al., 2006). 
Tissue features 
The Gene RPKM RNA-Seq data from the Genotype-Tissue Expression (GTEx) 
project(Consortium, 2015) was downloaded from 
http://www.gtexportal.org/home/. This dataset has 2921 samples spanning 30 
tissues. For each tissue, the median RPKM was calculated for each gene. For 
drugs with more than one target gene, the maximum RPKM was used. 
Target Loss Frequency 
The Exome Aggregation Consortium (ExAC) database (Exome Aggregation 
Consortium (ExAC)) was downloaded from www.exac.broadinstitute.org. For 
each gene, we counted the deleterious and total number of mutations that was 
reported. We calculated the loss frequency to be percentage of mutations that 
were reported in the gene that were deleterious. 
The PrOCTOR Model 
We trained the PrOCTOR approach on the clinical trials dataset using the 
features described above. It was trained using the random forest model, an 
ensembl decision tree based approach, which constructs 50 bootstrapped 
decision trees. A sub-sampling approach was used to account for the imbalanced 
ratio of approved drugs to FTT drugs, by randomly sampling the FDA approved 
class of samples to the size of the FTT drugs. To reduce the odds of poor 
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representatives being sampled, this was repeated 30 times. The labels were 
assigned by taking the consensus across the set of bootstrapped trees and 
replicates. This approach also yields a probability for each test sample. This 
probability was used to calculate an odds score = !(#$$%&'#()!(*#+(,%-) . To better visualize 
the distribution of this score, the log2 of the odds score was used. 
Independent Datasets 
To further assess our approach, we applied PrOCTOR to European (EMA) and 
Japanese (JP17) approved drugs, as well as 3236 drugs in DrugBank (version 
4.2) (Law et al., 2014).  The list of EMA-approved drugs were downloaded from 
the EMA website (http://www.ema.europa.eu/ema) and the JP17 list was 
downloaded from KEGG(Anders et al., 2015). Drugs that were already annotated 
as FDA approved were removed from these lists and the trained PrOCTOR 
model was used to make predictions for the remaining drugs. The openFDA 
resource (https://open.fda.gov) was used to query adverse events of drugs in the 
DrugBank dataset but not in our training set. FDA annotated drug-induced liver 
toxicity (DILI). The DILI dataset was downloaded from the FDA website at 
http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledg
eBase/ucm226811.htm. The SIDER side effect resource database (Kuhn et al., 
2010) was used to annotate side effects of each drug in the clinical trials dataset. 
The meddra_adverse_effects.txt table was used to extract reported adverse 
events, using the MedDRA Preferred Term descriptor to group similar side 
effects.  
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Statistical Analyses 
We used area under the receiver operating characteristic (ROC) curve and 10-
fold cross validation to evaluate the predictive power of our approach. For the 
independent analysis of predictions in the DrugBank dataset, we tested for 
enrichment of drug classes using the binomial test. We tested for differences of 
serious adverse event frequency between predicted toxic (score<-1) and 
predicted safe (score>1) drugs in the DrugBank dataset and not in the training 
set using the unpaired Student’s t-test. For the EMA, JP17, and DILI datasets, 
we tested for differences in PrOCTOR scores between predictions using the 
Mann-Whitney U Test. For the side effects of drugs in the training set, we used 
the Fisher’s Exact Test to identify the side effects that occurred more frequently 
in predicted toxic drugs using a p-value cutoff of 0.01. 
 
MATERIALS AND METHODS – Drug Combination Predictions 
The Model 
150 Single agent and 780 combinatorial efficacies were obtained from the Held 
et al (Held et al., 2013) study. The single agent efficacies were collapsed to their 
GI50 values, which is the concentration of the drug required to inhibit 50% of cell 
growth. Features representing a drug pair were constructed by taking the mean 
and difference (Figure 4.1) of the GI50 values for each of 27 tested cell lines (15 
mutant BRAF, 6 mutant RAS, 6 wtBRAF/wtRAS). 
The combinatorial results in 19 cell lines (8 mutant BRAF, 6 mutant RAS, and 5 
WT) were then used to construct labels for each of the 780 drug pairs. Genotype-
selective combinations were defined to be those that yielded an average 15% or 
greater growth inhibition exclusively in the genotypic group and achieved at least 
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50% growth inhibition within the genotypic group and a general effective 
combination was defined to be one that achieved at least 70% growth inhibition. 
Synergy labels for each combination were determined using the Chou-Talalay 
synergy combination index (CI) metric. We defined a synergistic combination to 
be a pair of drugs that yielded a CI less than -1 at any concentration level. A 
random forest model was then trained on the above-described data and 
evaluated using 10-fold cross-validation. Predictions were made using the trained 
model for the 10,395 untested combinations that had single agent efficacy 
information in the dataset. 
Experimental validation 
Melanoma Cell Culture 
Malme-3m, SK-Mel-28, and SK-MEL-2 cell lines were generously donated by the 
Houvras lab at Weill Cornell Medicine. Cell lines were cultured in basal medium 
[DMEM (Gibco) supplanted with 10% FBS and 1% penicillin/streptomycin (P/S)] 
and maintained in a 37° incubator at 5% CO2. 
Agent Screening 
Cells were pipetted into 384-well plates at 750 cells per well using a multi-
channel pipette (Eppendorf) in 20 ul basal medium, and placed in an 37° 
incubator at 5% CO2 overnight prior to exposure to the agent. Drug stock plates 
for single therapy agents were created by serial dilution, generally 1:10 from 10 
mmol/L stock. Using a multi-channel pipette, 2.5 ul drug volume from drug stock 
plates were added to the 384-well cell plates. A total of 0.1% and 10% DMSO 
was used as negative and positive controls, respectively. 
For combinatorial, dual-agent screens, a 2.5 ul volume of Drug X was plated at 
GI-50 concentration (determined from single-agent screen), and 2.5 ul volume 
  69 
from drug stock plate of Drug Y was added in a range of concentrations. Initial 
dual agent screening was carried out in 384-well plates at 750 cells per well in 20 
ul basal medium Further exploration screening were carried out in 96-well plates, 
in 100ul basal medium with 3500 cells per well. 
All experiments were carried out in triplicates at the Weill Cornell Medicine’s 
Meyer Cancer Center (WCMC MCC, New York, NY). Cells were exposed to 
drugs for 72 hours, followed by GI measurement by CellTiter-Glo ATP detection 
assay (Promega) following the manufacturer’s recommended. A 20 ul volume of 
basal medium served as a background for luminescence.  
Prediction Evaluation 
A combination was considered to be effective if the third quantile value of 
observed growth inhibition values was at least 70%. Synergistic combinations 
were those that achieved a Chou-Talalay synergy score of -1 in at least one 
dosage-level pair.  
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